Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

Acquisition Numbers Rise, Values Fall In Q1

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

Multiple stock graphs and numerical data overlaid on a cityscape, representing the finance and economy
Deals are happening, but they are not as large as in 2023 • Source: Shutterstock

Business development executives on site at this year’s BIO International Convention in San Diego noted that while the total dollar value of deals announced so far in 2024 may not be as high as it was at mid-year in 2023, negotiations for new partnerships and M&A are keeping dealmakers busy.

Key Takeaways

  • Business development executives and investors at the BIO International Convention said that biopharma dealmaking activity in 2024 is robust despite shifts in focus for big pharma.

Biomedtracker reported 39 M&A deals totaling $37bn during the first quarter of 2024, an improvement in terms of the number...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from BIO

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

 
• By Mandy Jackson

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

 
• By Mandy Jackson

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow

 
• By Mandy Jackson

Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.

More from Conferences

ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

 
• By Alexandra Shimmings

AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.    

ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM

 
• By Alexandra Shimmings

Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.    

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.